categories based on the reason for discordance, including (1) therapy mismatched with hormone receptor (HR) or HER2 status, (2) HER2-targeted therapy without chemotherapy, (3) nonapproved bevacizumab use, (4) adjuvant regimens received in the metastatic
Search Results
Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer
Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque
Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking
Lotte Bakkerus, Laurien M. Buffart, Tineke E. Buffart, Yannick M. Meyer, Barbara M. Zonderhuis, Cornelis J.A. Haasbeek, Kathelijn S. Versteeg, Olaf J.L. Loosveld, Jan Willem B. de Groot, Mathijs P. Hendriks, Cornelis Verhoef, Hendrik M.W. Verheul, and Elske C. Gootjes
fluoropyrimidines and oxaliplatin with or without bevacizumab), patients were randomized between continuation of systemic therapy (standard arm) or maximal tumor debulking followed by continuation of systemic therapy (intervention arm). Maximal tumor debulking is
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer
Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook
with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use
HSR19-077: Primary Tumor Location (PTL) and Survival Outcomes in a Real World Cohort of KRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC) Patients in the United States
Himani Aggarwal, Kristin M. Sheffield, Li Li, David Lenis, Rachael Sorg, and Rebecca Miksad
Background: PTL is a prognostic factor for mCRC. Recent data suggest PTL is also predictive of survival benefit with cetuximab (CET) and bevacizumab (BEV). This study evaluated the prognostic and predictive effect of PTL in patients with KRAS WT
The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know
Andrew D. Zelenetz
Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However, despite the fact that biosimilars (eg, filgrastim‐sndz, bevacizumab‐awwb, trastuzumab‐dkst, rituximab-abbs) have been approved in the United States, many clinicians are poorly informed about their unique pathway for approval. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, outlined important issues regarding the use of biosimilars, including extrapolation, interchangeability, and naming.
Discussing Colorectal Cancer
Paul F. Engstrom
Adjuvant Therapy for Stage II Colon Cancer: Prognostic and Predictive Markers
Brian Vicuna and Al B. Benson III
The treatment of stage II colon cancer is a controversial issue that has persisted for the past decade. Clinicians must understand that accurate assessment of risk factors is the key to identifying patients who will benefit from treatment. Pathologic staging for colon cancer is based on the American Joint Committee on Cancer 6th edition staging system. In addition, distinct pathologic factors characterize a patient at high risk for stage II disease. More recent retrospective data suggest that molecular markers and gene expression microarrays may be valuable as prognostic and predictive tests. Unfortunately, previous research studies were not powered to properly assess efficacy in stage II disease. However, 2 recent clinical trials, National Surgical Adjuvant Breast and Bowel Project C-07 and MOSAIC, have provided more insight into defining the optimal treatment approach. With the development of the newer therapeutic agents, oxaliplatin and bevacizumab, ongoing trials such as Intergroup E5202 should help determine risk versus benefit of chemotherapy in the adjuvant treatment of stage II colon cancer.
Chemotherapy for Advanced, Recurrent, and Metastatic Cervical Cancer
David H. Moore
When cervical cancer is beyond curative treatment with surgery or radiation therapy, the prognosis is poor and palliation is the primary objective. Early prospective studies identified cisplatin as an active drug for advanced, metastatic, or recurrent cervical cancer, and results with other platinum analogs seemed inferior to cisplatin. Several phase III trials have established the combination of cisplatin plus paclitaxel as standard therapy for comparison. Using pooled data from 3 Gynecologic Oncology Group (GOG) phase III studies, a predictive model was developed to better identify patients who are unlikely to respond to cisplatin-containing chemotherapy. The GOG is currently developing a phase III trial to investigate the impact of bevacizumab and a regimen containing topotecan instead of cisplatin in combination with paclitaxel chemotherapy and also to externally validate the predictive model. This study has the potential to radically change standard care for cervical cancer chemotherapy. Furthermore, if the predictive model is upheld, then patients with high risk factors for treatment failure may be directed to chemotherapy regimens that do not include cisplatin or to investigational trials.
Highlights of the NCCN Oncology Research Program
overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of TAS-102, Irinotecan, and Bevacizumab in Pretreated Metastatic Colorectal Cancer (TABAsCO) Principal Investigator: Christos
Highlights of the NCCN Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of TAS-102, Irinotecan, and Bevacizumab in Pretreated Metastatic Colorectal Cancer (TABAsCO) Principal Investigator: Christos Fountzilas, MD